INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

Also called NCT03539302

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (enrolled count) (from the registry)
Sponsor
InCarda Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT03539302
Other papers using this trial's data
  • Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial JACC. Clinical electrophysiology, 2024-06 DOI, PubMed 38613545

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03539302. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-29 (actual); primary completion 2022-01-17 (actual). Results posted on 2024-05-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
Acronym
INSTANT
Condition
Paroxysmal Atrial Fibrillation (PAF)
Intervention (Drug)
Flecainide Acetate
Lead sponsor
InCarda Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03539302
Content hash
74454af2f9c63c0360716d15dcceff1203ccd8b4cf1e81ccbed3e53a18cd9431